GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Essex Bio-Technology Ltd (HKSE:01061) » Definitions » Cash Conversion Cycle

Essex Bio-Technology (HKSE:01061) Cash Conversion Cycle : 226.09 (As of Dec. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Essex Bio-Technology Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Essex Bio-Technology's Days Sales Outstanding for the six months ended in Dec. 2024 was 119.79.
Essex Bio-Technology's Days Inventory for the six months ended in Dec. 2024 was 127.06.
Essex Bio-Technology's Days Payable for the six months ended in Dec. 2024 was 20.76.
Therefore, Essex Bio-Technology's Cash Conversion Cycle (CCC) for the six months ended in Dec. 2024 was 226.09.


Essex Bio-Technology Cash Conversion Cycle Historical Data

The historical data trend for Essex Bio-Technology's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Essex Bio-Technology Cash Conversion Cycle Chart

Essex Bio-Technology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 362.41 272.21 388.92 237.67 229.65

Essex Bio-Technology Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 363.26 241.34 244.22 235.34 226.09

Competitive Comparison of Essex Bio-Technology's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, Essex Bio-Technology's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Essex Bio-Technology's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Essex Bio-Technology's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Essex Bio-Technology's Cash Conversion Cycle falls into.


;
;

Essex Bio-Technology Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Essex Bio-Technology's Cash Conversion Cycle for the fiscal year that ended in Dec. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=118.95+129.83-19.13
=229.65

Essex Bio-Technology's Cash Conversion Cycle for the quarter that ended in Dec. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=119.79+127.06-20.76
=226.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Essex Bio-Technology  (HKSE:01061) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Essex Bio-Technology Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Essex Bio-Technology's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Essex Bio-Technology Business Description

Traded in Other Exchanges
N/A
Address
No. 88, Keji 6th Road, Hi-Tech Zone, Guangdong, Zhuhai, CHN
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel and mouth wash. The majority of the groups revenue comes from PRC.
Executives
Lauw Hui Kian
Ngiam Mia Je Patrick
Ngiam Mia Kiat Benjamin 2101 Beneficial owner

Essex Bio-Technology Headlines

No Headlines